Last reviewed · How we verify
A combination of Gemcitabine and cisplatin
A combination of Gemcitabine and cisplatin is a Small molecule drug developed by Cancer Hospital of Guangxi Medical University. It is currently in Phase 2 development. Also known as: GP.
At a glance
| Generic name | A combination of Gemcitabine and cisplatin |
|---|---|
| Also known as | GP |
| Sponsor | Cancer Hospital of Guangxi Medical University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Nausea
- Decreased appetite
- Constipation
- Neutrophil count decreased
- Platelet count decreased
- Fatigue
- Neutropenia
- Asthenia
- Vomiting
- White blood cell count decreased
- Diarrhoea
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (PHASE1)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A combination of Gemcitabine and cisplatin CI brief — competitive landscape report
- A combination of Gemcitabine and cisplatin updates RSS · CI watch RSS
- Cancer Hospital of Guangxi Medical University portfolio CI
Frequently asked questions about A combination of Gemcitabine and cisplatin
What is A combination of Gemcitabine and cisplatin?
A combination of Gemcitabine and cisplatin is a Small molecule drug developed by Cancer Hospital of Guangxi Medical University.
Who makes A combination of Gemcitabine and cisplatin?
A combination of Gemcitabine and cisplatin is developed by Cancer Hospital of Guangxi Medical University (see full Cancer Hospital of Guangxi Medical University pipeline at /company/cancer-hospital-of-guangxi-medical-university).
Is A combination of Gemcitabine and cisplatin also known as anything else?
A combination of Gemcitabine and cisplatin is also known as GP.
What development phase is A combination of Gemcitabine and cisplatin in?
A combination of Gemcitabine and cisplatin is in Phase 2.
What are the side effects of A combination of Gemcitabine and cisplatin?
Common side effects of A combination of Gemcitabine and cisplatin include Anaemia, Nausea, Decreased appetite, Constipation, Neutrophil count decreased, Platelet count decreased.
Related
- Manufacturer: Cancer Hospital of Guangxi Medical University — full pipeline
- Also known as: GP
- Compare: A combination of Gemcitabine and cisplatin vs similar drugs
- Pricing: A combination of Gemcitabine and cisplatin cost, discount & access